AOD
AOD-9604
A synthetic peptide corresponding to residues 176 to 191 of human growth hormone, with a tyrosine added at the N-terminus. It is a fragment, not the hormone: it lacks the regions of growth hormone that bind the growth hormone receptor. No receptor target for the fragment itself has been established in the published literature, so none is stated here.
No registered human study names AOD-9604 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains AOD-9604. 4 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names AOD-9604; the registry search is fuzzy, so every match is re-checked. None of this says whether AOD-9604 works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
4
Readership
26
monthly average, Apr–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of AOD-9604 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What AOD-9604 is, and what it has been studied for
AOD-9604 is classified by ChEMBL as a protein, and appears in trial registrations under LAT-8881 and LAT8881.
No registered trial names AOD-9604 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 4 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying AOD-9604?
Papers published each year that name AOD-9604 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 0 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 4 | 0 | No |
4 papers between 2017 and 2026. A paper counts when “AOD9604” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on AOD-9604
4 indexed papers name AOD-9604 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- AOD-9604 Metabolic
- Detection and in vitro metabolism of AOD9604
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Collected 2026-08-02from PubMed, phrase-matched on “AOD9604” in title and abstract. Run the same search.
About AOD-9604
A synthetic peptide corresponding to residues 176 to 191 of human growth hormone, with a tyrosine added at the N-terminus. It is a fragment, not the hormone: it lacks the regions of growth hormone that bind the growth hormone receptor. No receptor target for the fragment itself has been established in the published literature, so none is stated here.
- Also known as
- AOD9604 · hGH 177-191
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.